Home  /  Resource Library  /  Pharmacokinetics and Exposure-Response Analysis of Venetoclax+Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial

Pharmacokinetics and Exposure-Response Analysis of Venetoclax+Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial

Study investigated venetoclax combined with obinutuzumab for first line treatment of CLL.